Labcorp Receives FDA De Novo Marketing Authorization For PGDx elio plasma focus Dx, Pan-Solid Tumor Liquid Biopsy Test
Portfolio Pulse from Benzinga Newsdesk
Labcorp has received FDA De Novo marketing authorization for its PGDx elio plasma focus Dx, a pan-solid tumor liquid biopsy test. This is the first kitted test of its kind, allowing for tumor mutation profiling from a simple blood draw.

August 02, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Labcorp has received FDA De Novo marketing authorization for its PGDx elio plasma focus Dx, a pan-solid tumor liquid biopsy test. This is the first kitted test of its kind, allowing for tumor mutation profiling from a simple blood draw.
The FDA De Novo marketing authorization is a significant regulatory milestone for Labcorp, likely to boost investor confidence and potentially increase the stock price in the short term. The uniqueness of the product as the first kitted pan-solid tumor liquid biopsy test adds to its market potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100